Lymphoma Clinical Trials

Showing 261-280 of 2,926 trials

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

NCT03938987

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL

University of Alberta63 participantsStarted Mar 2021

Calgary, Alberta, Canada • Calgary, Alberta, Canada • Calgary, Alberta, Canada +3 more locations

COMPLETED

Cardiovascular Effects of CART Cell Therapy

NCT04026737

This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular events. The study enrolls patients prior to infusion with CART cell therapy and follows them with serial echocardiography, cardiac biomarkers, clinical data, and quality of life questionnaire.

LeukemiaLymphomaCardiotoxicity+2 more

Abramson Cancer Center at Penn Medicine44 participantsStarted Jul 2019

Philadelphia, Pennsylvania, United States

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Cardiovascular Effects of CART Cell Therapy

Related Searches

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Vaccine Responses in Patients With B Cell Malignancies

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

A Study of CTD402 in T-ALL/LBL Patients

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL